Personalis (NASDAQ:PSNL) PT Raised to $9.00 at HC Wainwright

Personalis (NASDAQ:PSNL) had its price objective increased by analysts at HC Wainwright from $7.50 to $9.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 50.25% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Lake Street Capital assumed coverage on Personalis in a research report on Tuesday, April 30th. They set a “buy” rating and a $4.00 price objective for the company. BTIG Research lifted their target price on Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a report on Friday. Finally, Needham & Company LLC lifted their target price on Personalis from $5.50 to $7.25 and gave the stock a “buy” rating in a report on Friday.

Personalis Trading Up 18.1 %

Shares of PSNL stock opened at $5.99 on Monday. The business’s 50-day moving average price is $2.35 and its 200-day moving average price is $1.75. Personalis has a 12 month low of $0.89 and a 12 month high of $7.20. The firm has a market capitalization of $317.95 million, a price-to-earnings ratio of -3.15 and a beta of 1.85.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The firm had revenue of $22.58 million for the quarter, compared to analyst estimates of $19.81 million. During the same period last year, the firm posted ($0.50) earnings per share. On average, sell-side analysts predict that Personalis will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PSNL. GSA Capital Partners LLP boosted its position in Personalis by 6.2% in the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after purchasing an additional 24,498 shares during the last quarter. Acadian Asset Management LLC boosted its position in Personalis by 90.7% in the first quarter. Acadian Asset Management LLC now owns 991,828 shares of the company’s stock worth $1,476,000 after purchasing an additional 471,646 shares during the last quarter. State of Michigan Retirement System boosted its position in Personalis by 11.3% in the first quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after purchasing an additional 50,000 shares during the last quarter. Bruce & Co. Inc. raised its stake in shares of Personalis by 100.0% in the fourth quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock valued at $630,000 after buying an additional 150,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Personalis by 144.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock valued at $1,224,000 after buying an additional 485,822 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.